Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Aesthetic treatments can safely improve cancer patients' quality of life with oncologist approval.

Scalp cooling reduces chemotherapy-induced hair loss without increasing risk of skin metastases.

The tool accurately tracks eyebrow hair loss in chemotherapy patients.

Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Antiandrogen therapy helped increase hair growth in women with hormonal imbalances related to baldness.

Chemotherapy and radiotherapy do not significantly affect obstructive sleep apnea development.

A man's skin cancer improved and some of his hair grew back after treatment with a special light therapy and a medication.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

ODC expression in mouse skin and tumors is varied and can be inhibited by retinoic acid or cycloheximide.

Cooling the scalp below 22°C before and during chemotherapy can help prevent hair loss.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

A botanical extract was found to be a safe treatment that may prevent hair loss in chemotherapy patients.

AS101 reduces hair loss from chemotherapy.

Scalp cooling and low-power light therapy show promise in reducing chemotherapy-induced hair loss but need more research.

Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.

Chemotherapy improved a girl's painful foot condition linked to pachyonychia congenita.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.

CTP-543 is generally safe for treating alopecia areata.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Perhexiline can effectively target ovarian cancer cells left after treatment.

Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.